Olema Pharmaceuticals, Inc. reports clinical, corporate, and financing developments as a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other cancers. Olema Oncology updates commonly center on palazestrant (OP-1250), an orally available complete estrogen receptor antagonist and selective estrogen receptor degrader, and OP-3136, an orally available KAT6 inhibitor.
Recurring company news covers clinical and preclinical presentations at oncology meetings, endocrine-driven cancer biology, ER+/HER2- breast cancer studies, combination approaches with endocrine therapy and CDK inhibitors, operating results, public offerings, inducement equity grants, and board or management changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on targeted therapies for women’s cancers, announced the participation of its President and CEO, Sean Bohen, in a panel discussion on “ER+/HER2- Breast Cancer” at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference. This event is scheduled for April 20, 2023, at 2:00 p.m. ET.
Olema's lead product candidate, OP-1250, is an innovative treatment designed as both a complete estrogen receptor antagonist and a selective estrogen receptor degrader. Currently in a Phase 2 clinical trial, OP-1250 is being assessed as a single agent and in combination with existing therapies for patients with recurrent advanced ER-positive, HER2-negative breast cancer. The FDA has granted it Fast Track designation for treating metastatic cases that have failed prior endocrine therapies.
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) announced the grant of stock options to two new employees, totaling 11,800 shares, effective April 3, 2023. The options, part of the 2022 Inducement Plan, vest over four years, with 25% on the first anniversary and the remainder monthly for three years. The exercise price is set at $3.49, reflecting the last reported stock price. This move underscores Olema's commitment to attracting talent as it develops targeted therapies for women’s cancers, particularly the lead candidate, OP-1250, which is in Phase 2 trials for ER-positive breast cancer.
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) reported significant progress in its lead program, OP-1250, with over 170 patients treated. The company is set to initiate its first pivotal Phase 3 trial of OP-1250 for metastatic breast cancer in the latter half of 2023. Financially, Olema held $204.4 million in cash as of December 31, 2022, sufficient to fund operations through 2025. However, the company reported a net loss of $26.2 million for Q4 and $104.8 million for the full year, driven by increased R&D spending. Organizational restructuring will reduce the workforce by 25% to focus on OP-1250’s late-stage development.